AI-generated summary
In this animal study, the authors tested thymoquinone alone, transcranial photobiomodulation alone, and their combination after induced brain ischemia in rats. The combined treatment was reported to reduce neurological deficit scores, infarct volume and brain edema compared with the ischemia group, with higher BDNF gene expression. The findings come from a rat model at 24 hours after reperfusion, so applicability to humans is not established.
- Participants
- 85
- Who or what was studied
- Wistar male rats (animal model of middle cerebral artery occlusion)
- Wavelengths
- 810 nm
- Limits stated in the abstract
- Findings are from an animal model assessed only at 24 hours after reperfusion, so short-term and not shown to apply to humans.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 810 nm
- Power
- 8 mW
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Transcranial photobiomodulation, Photobiomodulation, Low-level laser therapy, Laser, Sham, Fluence. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.